The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
CTLA-4: a negative regulator of autoimmune disease.
Open accessAbstract
CTLA-4, a CD28 homologue expressed on activated T cells, binds with high affinity to the CD28 ligands, B7-1 (CD80) and B7-2 (CD86). This study was designed to examine the role of CTLA-4 in regulating autoimmune disease. Murine relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE) is a demyelinating disease mediated by PLP139-151-specific CD4+ T cells in SJL/J mice. Anti-CTLA-4 mAbs (or their F(ab) fragments) enhanced in vitro proliferation and pro-inflammatory cytokine production by PLP139-151-primed lymph node cells. Addition of either reagent to in vitro activation cultures potentiated the ability of T cells to adoptively transfer disease to naive recipients. In vivo administration of anti-CTLA-4 mAb to recipients of PLP139-151-specific T cells resulted in accelerated and exacerbated disease. Finally, anti-CTLA-4 treatment of mice during disease remission resulted in the exacerbation of relapses. Collectively, these results suggest that CTLA-4 mediates the downregulation of ongoing immune responses and plays a major role in regulating autoimmunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Self-citationLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“Cross-linking of CTLA-4 after the ligation of CD3 and CD28 strongly inhibited proliferation and IL-2 production (14).”
BackgroundCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Self-citationCTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Kuchroo, V. K., Prabhu Das, M., Brown, J. A., Ranger, A. M., Zamvil, S. S., Sobel, R. A., Weiner, H. L., Nabavi, N., & Glimcher, L. H. (1995) · Cell · doi:10.1016/0092-8674(95)90349-6 · Cited by 1,641
Mueller, D. L., Jenkins, M. K., & Schwartz, R. H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.002305 · Cited by 1,493
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg
Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., Montag, A., Brady, W., Gibson, M. G., Linsley, P. S., & Bluestone, J. A. (1992) · Science · doi:10.1126/science.1323143 · Cited by 1,121
Self-citationCTLA-4 ligation blocks CD28-dependent T cell activation.
Walunas, T. L., Bakker, C. Y., & Bluestone, J. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2541 · Cited by 801
Self-citationImmunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule
Linsley, P. S., Wallace, P. M., Johnson, J., Gibson, M. G., Greene, J. L., Ledbetter, J. A., Singh, C., & Tepper, M. A. (1992) · Science · doi:10.1126/science.1496399 · Cited by 790
Lenschow, D. J., Ho, S. C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., Herold, K. C., & Bluestone, J. A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.3.1145 · Cited by 583
Self-citationCoexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Linsley, P. S., Greene, J. L., Tan, P., Bradshaw, J., Ledbetter, J. A., Anasetti, C., & Damle, N. K. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1595 · Cited by 581
McRae, B. L., Vanderlugt, C. L., Dal Canto, M. C., & Miller, S. D. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.75 · Cited by 518
Self-citationDeterminant spreading and the dynamics of the autoimmune T-cell repertoire
Lehmann, P. V., Sercarz, E. E., Forsthuber, T., Dayan, C. M., & Gammon, G. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90163-f · Cited by 461
Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE
Miller, S. D., Vanderlugt, C. L., Lenschow, D. J., Pope, J. G., Karandikar, N. J., Dal Canto, M. C., & Bluestone, J. A. (1995) · Immunity · doi:10.1016/1074-7613(95)90063-2 · Cited by 315
Self-citationKearney, E. R., Walunas, T. L., Karr, R. W., Morton, P. A., Loh, D. Y., Bluestone, J. A., & Jenkins, M. K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1032 · Cited by 312
Self-citationDariavach, P., Mattéi, M., Golstein, P., & Lefranc, M. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181206 · Cited by 301
McRae, B. L., Kennedy, M. K., Tan, L.-J., Dal Canto, M. C., Picha, K. S., & Miller, S. D. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90016-e · Cited by 241
Self-citationThe immunopathogenesis and regulation of T-cell-mediated demyelinating diseases
Miller, S. D., & Karpus, W. J. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90173-2 · Cited by 163
Self-citationINHIBITION OF TRANSPLANT REJECTION FOLLOWING TREATMENT WITH ANTI-B7-2 AND ANTI-B7-1 ANTIBODIES
Lenschow, D. J., Zeng, Y., Hathcock, K. S., Zuckerman, L. A., Freeman, G., Thistlethwaite, J. R., Gray, G. S., Hodes, R. J., & Bluestone, J. A. (1995) · Transplantation · doi:10.1097/00007890-199511270-00019 · Cited by 160
Self-citationPerrin, P. J., Scott, D. E., Quigley, L., Albert, P. S., Feder, O., Gray, G. S., Abe, R., June, C. H., & Racke, M. K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.3.1481 · Cited by 146
Damle, N. K., Klussman, K., Leytze, G., Myrdal, S. E., Aruffo, A. A., Ledbetter, J. A., & Linsley, P. S. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.6.2686 · Cited by 87
T cell co-stimulation and in vivo tolerance
Lenschow, D. J., & Bluestone, J. A. (1993) · Current Opinion in Immunology · doi:10.1016/0952-7915(93)90132-c · Cited by 77
Self-citationImmunopathogenesis of multiple sclerosis.
Wekerle, H. (1991) · PubMed · Cited by 56
Cited by
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Self-citationAnti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,161
Metadata
- Authors
- Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D., & Bluestone, J. A.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1996-08-01
- Volume
- 184
- Issue
- 2
- Pages
- 783-788
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2114329158
- Cited by
- 376
- References
- 26
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.